|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:abusePotential
|
high
|
|
gptkbp:activeIngredient
|
gptkb:oxycodone
|
|
gptkbp:antidote
|
gptkb:naloxone
|
|
gptkbp:approvalYear
|
1995
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:oxycodone_extended-release
|
|
gptkbp:controlledSubstanceSchedule
|
gptkb:Schedule_II_(US)
|
|
gptkbp:controversy
|
opioid epidemic
|
|
gptkbp:drugClass
|
opioid
|
|
gptkbp:form
|
extended-release tablet
|
|
gptkbp:genericAvailable
|
yes
|
|
gptkbp:halfLife
|
3-4.5 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
OxyContin
|
|
gptkbp:indication
|
moderate to severe pain
|
|
gptkbp:lawsuit
|
gptkb:Purdue_Pharma_settlement
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Purdue_Pharma
|
|
gptkbp:marketedAs
|
gptkb:United_States
|
|
gptkbp:marketedIn
|
gptkb:Australia
gptkb:Canada
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:prescriptionRequired
|
yes
|
|
gptkbp:riskFactor
|
addiction
overdose
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
constipation
drowsiness
respiratory depression
|
|
gptkbp:bfsParent
|
gptkb:Dopesick
gptkb:Napp_Pharmaceuticals
gptkb:Pain_Killer:_An_Empire_of_Deceit_and_the_Origin_of_America’s_Opioid_Epidemic
gptkb:Sackler_family
gptkb:Purdue_Pharma
|
|
gptkbp:bfsLayer
|
6
|